Vascular Biogenics Ltd (VBLT)

[gr8db8]

Phase 2 and 3 are different:

ph2) Single-Arm Open-Label
https://clinicaltrials.gov/ct2/show/NCT01260506
In the first stage of the study, patients were treated with VB-111 alone. Upon disease progression, patients entered the second stage of the study, in which they received either Avastin alone as standard of care (limited exposure cohort) or VB-111 in combination with Avastin (continuous exposure cohort).

ph3) Randomized, Controlled, Double-Arm, Open-Label, VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy